| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2013082345 |
| Title |
Aryl Dihydropyridinones and Piperidinones As Mgat2 Inhibitors. |
| Abstract |
The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Representative Drug(s) |
D0F2KN |
Drug Info
|
IC50 = 14 nM |
Click to Show More |
[1] |
|
2
|
D0U2WQ
|
Drug Info
|
IC50 = 1435 nM
|
[1] |
| Patent ID |
WO2013112323 |
| Title |
Phenyl Methanesulfonamide Derivatives Useful As Mgat - 2 Inhibitors. |
| Abstract |
The present invention provides compounds of Formula I or a pharmaceutical salt thereof, where the variables for R1, R2, and R3 are as described herein; methods of treating a condition such as hypertriglyceridemia; and processes for preparing the compounds. |
| Applicant(s) |
Eli Lilly and Company |
| Representative Drug(s) |
D0B7JY |
Drug Info
|
IC50 = 12 nM |
[1] |
| Patent ID |
WO2012124744 |
| Title |
Nitrogen-Containing Condensed Heterocyclic Compound. |
| Abstract |
Provided is a compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, having superior monoacylglycerol acyltransferase-2 inhibitory activity. In formula (I), ring (A) represents a partially saturated heteroaryl group, an aryl group, or a heteroaryl group; RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or formula (II) (in formula (II), V represents the formula -CR11R12-, the formula -CO-, the formula -CO-O-, or the formula -CO-NH-; W represents a single bond or a C1-3 alkylene group; and the ring (B) represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group); Y represents a nitrogen atom or formula N+(RF); RF represents a C1-4 alkyl group; and m and n may be the same or different and each independently represent an integer 0 or 1. |
| Applicant(s) |
Taisho Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0NY3W |
Drug Info
|
IC50 = 2 nM |
[1] |
| Patent ID |
WO2012091010 |
| Title |
Bicyclic Pyrimidine Derivative. |
| Abstract |
The purpose of the present invention is to provide: a compound which has a MGAT inhibitory effect and is useful as a pharmaceutical product, or a physiologically acceptable salt of the compound; and a pharmaceutical composition which contains the compound or a physiologically acceptable salt of the compound. A bicyclic pyrimidine compound represented by formula (I) or a physiologically acceptable salt thereof. (In the formula, R1 represents an optionally substituted lower alkyl group or the like; R2 represents a hydrogen atom or the like; R3 represents a hydrogen atom or the like; R4 and R5 each independently represents a hydrogen atom or the like; X represents an oxygen atom or the like; Y represents -N(R9)C(=Z)- (wherein R9 represents a hydrogen atom or the like and Z represents an oxygen atom or the like) or the like; m represents 1; and n represents 2.). |
| Applicant(s) |
Dainippon Sumitomo Pharma Co |
| Representative Drug(s) |
D0RC4W |
Drug Info
|
IC50 = 4.1 nM |
[1] |
| Patent ID |
WO2010095767 |
| Title |
Pyrimidin-4(3H)-One Derivatives. |
| Abstract |
The present invention relates to a compound represented by a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents lower alkyl or the like; R2 represents phenyl or the like; R represents a halogen atom or the like; X represents an oxygen atom or the like; Y1, Y2, Y3 and Y4 represent CH or the like; l represents an integer of from 0 to 3; m and n each represent an integer of 1 or 2; p represents an integer of from 0 to 2; and q represents an integer of from 1 to 3. |
| Applicant(s) |
Msd K.K |
| Representative Drug(s) |
D0MH7K |
Drug Info
|
IC50 = 56 nM |
[1] |
